Mariangela Biava

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4985792/publications.pdf

Version: 2024-02-01

75	2,493	172443	206102
papers	citations	29 h-index	48 g-index

81	81	81	3132
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	MmpL3 Is the Cellular Target of the Antitubercular Pyrrole Derivative BM212. Antimicrobial Agents and Chemotherapy, 2012, 56, 324-331.	3.2	190
2	Bactericidal Activities of the Pyrrole Derivative BM212 against Multidrug-Resistant and Intramacrophagic Mycobacterium tuberculosis Strains. Antimicrobial Agents and Chemotherapy, 1998, 42, 3035-3037.	3.2	156
3	Antimycobacterial Agents. Novel Diarylpyrrole Derivatives of BM212 Endowed with High Activity toward Mycobacterium tuberculosis and Low Cytotoxicity. Journal of Medicinal Chemistry, 2006, 49, 4946-4952.	6.4	104
4	Improved BM212 MmpL3 Inhibitor Analogue Shows Efficacy in Acute Murine Model of Tuberculosis Infection. PLoS ONE, 2013, 8, e56980.	2.5	90
5	1,5-Diphenylpyrrole Derivatives as Antimycobacterial Agents. Probing the Influence on Antimycobacterial Activity of Lipophilic Substituents at the Phenyl Rings. Journal of Medicinal Chemistry, 2008, 51, 3644-3648.	6.4	75
6	New pyrrole derivatives as antimycobacterial agents analogs of BM212. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 2983-2988.	2.2	74
7	A class of pyrrole derivatives endowed with analgesic/anti-inflammatory activity. Bioorganic and Medicinal Chemistry, 2013, 21, 3695-3701.	3.0	74
8	Importance of the thiomorpholine introduction in new pyrrole derivatives as antimycobacterial agents analogues of BM 212. Bioorganic and Medicinal Chemistry, 2003, 11, 515-520.	3.0	73
9	Antimycobacterial compounds. New pyrrole derivatives of BM212. Bioorganic and Medicinal Chemistry, 2004, 12, 1453-1458.	3.0	73
10	Dietary flavonoids: Nano delivery and nanoparticles for cancer therapy. Seminars in Cancer Biology, 2021, 69, 150-165.	9.6	71
11	1,5-Diaryl-2-ethyl pyrrole derivatives as antimycobacterial agents: Design, synthesis, and microbiological evaluation. European Journal of Medicinal Chemistry, 2009, 44, 4734-4738.	5.5	66
12	A Flow-Based Synthesis of 2-Aminoadamantane-2-carboxylic Acid. Organic Process Research and Development, 2012, 16, 798-810.	2.7	64
13	Inhibition of Leishmania infantum Trypanothione Reductase by Azoleâ€Based Compounds: a Comparative Analysis with Its Physiological Substrate by Xâ€ray Crystallography. ChemMedChem, 2013, 8, 1175-1183.	3.2	63
14	Activity of lipophilic and hydrophilic drugs against dormant and replicating Mycobacterium tuberculosis. Journal of Antibiotics, 2015, 68, 711-714.	2.0	61
15	Cyclooxygenase-2 Inhibitors. 1,5-Diarylpyrrol-3-acetic Esters with Enhanced Inhibitory Activity toward Cyclooxygenase-2 and Improved Cyclooxygenase-2/Cyclooxygenase-1 Selectivity. Journal of Medicinal Chemistry, 2007, 50, 5403-5411.	6.4	56
16	Antimycobacterial compounds. Optimization of the BM 212 structure, the lead compound for a new pyrrole derivative class. Bioorganic and Medicinal Chemistry, 2005, 13, 1221-1230.	3.0	50
17	Synthesis, Biological Evaluation, and Enzyme Docking Simulations of 1,5-Diarylpyrrole-3-Alkoxyethyl Ethers as Selective Cyclooxygenase-2 Inhibitors Endowed with Anti-inflammatory and Antinociceptive Activity. Journal of Medicinal Chemistry, 2008, 51, 4476-4481.	6.4	50
18	Identification of a novel pyrrole derivative endowed with antimycobacterial activity and protection index comparable to that of the current antitubercular drugs streptomycin and rifampin. Bioorganic and Medicinal Chemistry, 2010, 18, 8076-8084.	3.0	48

#	Article	IF	Citations
19	Identification of potent c-Src inhibitors strongly affecting the proliferation of human neuroblastoma cells. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 5928-5933.	2.2	48
20	SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development. European Journal of Medicinal Chemistry, 2014, 86, 335-351.	5.5	45
21	1,5-Diarylpyrrole-3-acetic Acids and Esters as Novel Classes of Potent and Highly Selective Cyclooxygenase-2 Inhibitors. Journal of Medicinal Chemistry, 2005, 48, 3428-3432.	6.4	44
22	Novel Ester and Acid Derivatives of the 1,5-Diarylpyrrole Scaffold as Anti-Inflammatory and Analgesic Agents. Synthesis and in Vitro and in Vivo Biological Evaluation. Journal of Medicinal Chemistry, 2010, 53, 723-733.	6.4	43
23	Novel Analgesic/Anti-Inflammatory Agents: 1,5-Diarylpyrrole Nitrooxyalkyl Ethers and Related Compounds as Cyclooxygenase-2 Inhibiting Nitric Oxide Donors. Journal of Medicinal Chemistry, 2013, 56, 3191-3206.	6.4	43
24	Novel Analgesic/Anti-Inflammatory Agents: Diarylpyrrole Acetic Esters Endowed with Nitric Oxide Releasing Properties. Journal of Medicinal Chemistry, 2011, 54, 7759-7771.	6.4	42
25	Novel Pyrazole-Containing Compounds Active against Mycobacterium tuberculosis. ACS Medicinal Chemistry Letters, 2019, 10, 1423-1429.	2.8	37
26	Developing Pyroleâ€Derived Antimycobacterial Agents: a Rational Lead Optimization Approach. ChemMedChem, 2011, 6, 593-599.	3.2	35
27	COX inhibitors: a patent review (2011 â€“ 2014). Expert Opinion on Therapeutic Patents, 2015, 25, 1357-1371.	5.0	34
28	A Novel Antimycobacterial Compound Acts as an Intracellular Iron Chelator. Antimicrobial Agents and Chemotherapy, 2015, 59, 2256-2264.	3.2	33
29	Characterization of the biotransformation pathways of clomiphene, tamoxifen and toremifene as assessed by LC-MS/(MS) following in vitro and excretion studies. Analytical and Bioanalytical Chemistry, 2013, 405, 5467-5487.	3.7	31
30	New oxazolidinone derivatives as antibacterial agents with improved activity. Expert Opinion on Therapeutic Patents, 2008, 18, 97-121.	5.0	30
31	(E)-3-Heteroarylidenechroman-4-ones as potent and selective monoamine oxidase-B inhibitors. European Journal of Medicinal Chemistry, 2016, 117, 292-300.	5.5	30
32	In Vitro Effects of VA441, a New Selective Cyclooxygenase-2 Inhibitor, on Human Osteoarthritic Chondrocytes exposed to IL-1^|^beta;. Journal of Pharmacological Sciences, 2012, 120, 6-14.	2.5	29
33	1,5-Diphenylpenta-2,4-dien-1-ones as potent and selective monoamine oxidase-B inhibitors. European Journal of Medicinal Chemistry, 2013, 59, 91-100.	5.5	28
34	MmpL3 Inhibitors: Diverse Chemical Scaffolds Inhibit the Same Target. Mini-Reviews in Medicinal Chemistry, 2016, 16, 1274-1283.	2.4	28
35	Chondroprotective effect of three different classes of anti-inflammatory agents on human osteoarthritic chondrocytes exposed to IL-1Î². International Immunopharmacology, 2015, 28, 794-801.	3.8	27
36	Synthesis and biological evaluation of fluorinated 1,5-diarylpyrrole-3-alkoxyethyl ether derivatives as selective COX-2 inhibitors endowed with anti-inflammatory activity. European Journal of Medicinal Chemistry, 2016, 109, 99-106.	5.5	27

#	Article	IF	Citations
37	BM 212 and its Derivatives as a New Class of Antimycobacterial Active Agents. Current Medicinal Chemistry, 2002, 9, 1859-1869.	2.4	25
38	Enhancing the pharmacodynamic profile of a class of selective COX-2 inhibiting nitric oxide donors. Bioorganic and Medicinal Chemistry, 2014, 22, 772-786.	3.0	25
39	Antiproliferative effect of two novel COX-2 inhibitors on human keratinocytes. European Journal of Pharmaceutical Sciences, 2013, 49, 133-141.	4.0	22
40	InÂvivo potent BM635 analogue with improved drug-like properties. European Journal of Medicinal Chemistry, 2018, 145, 539-550.	5.5	22
41	Synthesis, biological evaluation and docking analysis of a new series of methylsulfonyl and sulfamoyl acetamides and ethyl acetates as potent COX-2 inhibitors. Bioorganic and Medicinal Chemistry, 2015, 23, 810-820.	3.0	21
42	N-((1,3-Diphenyl-1H-pyrazol-4-yl)methyl)anilines: A novel class of anti-RSV agents. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 2401-2404.	2.2	21
43	A fast virtual screening approach to identify structurally diverse inhibitors of trypanothione reductase. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 5255-5258.	2.2	19
44	Identification of Hck Inhibitors As Hits for the Development of Antileukemia and Antiâ€HIV Agents. ChemMedChem, 2013, 8, 1353-1360.	3.2	19
45	Synthesis, in vitro, and in vivo biological evaluation and molecular docking simulations of chiral alcohol and ether derivatives of the 1,5-diarylpyrrole scaffold as novel anti-inflammatory and analgesic agents. Bioorganic and Medicinal Chemistry, 2008, 16, 8072-8081.	3.0	18
46	Improving the solubility of a new class of antiinflammatory pharmacodynamic hybrids, that release nitric oxide and inhibit cycloxygenase-2 isoenzyme. European Journal of Medicinal Chemistry, 2012, 58, 287-298.	5.5	16
47	Flow Synthesis and Biological Studies of an Analgesic Adamantane Derivative That Inhibits P2X₇-Evoked Glutamate Release. ACS Medicinal Chemistry Letters, 2013, 4, 704-709.	2.8	16
48	HPLC enantioseparation and absolute configuration of novel antiâ€inflammatory pyrrole derivatives. Chirality, 2008, 20, 775-780.	2.6	12
49	In vitro comprehensive analysis of VA692 a new chemical entity for the treatment of osteoarthritis. International Immunopharmacology, 2018, 64, 86-100.	3.8	12
50	Mycobacterial tryptophan biosynthesis: A promising target for tuberculosis drug development?. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 126731.	2.2	12
51	SAR Analysis of Small Molecules Interfering with Energy-Metabolism in Mycobacterium tuberculosis. Pharmaceuticals, 2020, 13, 227.	3.8	12
52	Metabolomic Profiling of Fresh Goji (Lycium barbarum L.) Berries from Two Cultivars Grown in Central Italy: A Multi-Methodological Approach. Molecules, 2021, 26, 5412.	3.8	12
53	Antimycobacterial activity of new ortho-, meta- and para-toluidine derivatives. Il Farmaco, 1999, 54, 721-727.	0.9	11
54	Design, synthesis, and in vitro hMAO-B inhibitory evaluation of some 1-methyl-3,5-diphenyl-4,5-dihydro-1H-pyrazoles. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 5128-5130.	2.2	11

#	Article	IF	Citations
55	Overcoming drug resistance for tuberculosis. Future Microbiology, 2015, 10, 1735-1741.	2.0	11
56	Introduction to COX inhibitors. Future Medicinal Chemistry, 2018, 10, 1737-1740.	2.3	11
57	Neutrophil-to-Lymphocyte Ratio, Mediterranean Diet, and Bone Health in Coeliac Disease Patients: A Pilot Study. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-14.	4.0	11
58	Pharmaceutical salt of BM635 with improved bioavailability. European Journal of Pharmaceutical Sciences, 2017, 99, 17-23.	4.0	10
59	Pharmacophore Assessment Through 3-D QSAR: Evaluation of the Predictive Ability on New Derivatives by the Application on a Series of Antitubercular Agents. Journal of Chemical Information and Modeling, 2013, 53, 1463-1474.	5.4	9
60	Scale-Up of Flow-Assisted Synthesis of C2-Symmetric Chiral PyBox Ligands. Synthesis, 2012, 2012, 635-647.	2.3	6
61	A Series of COXâ€2 Inhibitors Endowed with NOâ€Releasing Properties: Synthesis, Biological Evaluation, and Docking Analysis. ChemMedChem, 2016, 11, 1804-1811.	3.2	6
62	Synthesis and antimycotic activity of new (1H-1,2,4-triazol-1-yl-methyl)benzeneamine derivatives. European Journal of Medicinal Chemistry, 1989, 24, 537-540.	5.5	5
63	Antifungal Agents, Part 11: Biphenyl Analogues of Naftifine: Synthesis and Antifungal Activities. Archiv Der Pharmazie, 1995, 328, 667-672.	4.1	5
64	An alternative synthetic approach for the synthesis of biologically relevant 1,4-disubstituted pyrazolo[3,4-d]pyrimidines. Tetrahedron Letters, 2013, 54, 5204-5206.	1.4	5
65	A Novel Class of Dual-Acting DCH-CORMs Counteracts Oxidative Stress-Induced Inflammation in Human Primary Tenocytes. Antioxidants, 2021, 10, 1828.	5.1	5
66	Malaria transmission blocking compounds: a patent review. Expert Opinion on Therapeutic Patents, 2022, 32, 649-666.	5.0	5
67	Nano-Based Drug Delivery Systems of Potent MmpL3 Inhibitors for Tuberculosis Treatment. Pharmaceutics, 2022, 14, 610.	4.5	5
68	1,5-Diarylpyrroles as potent antitubercular and anti-inflammatory agents. Chemistry of Heterocyclic Compounds, 2017, 53, 281-291.	1.2	4
69	Chocolate Consumers and Lymphocyte-to-Monocyte Ratio: A Working Hypothesis from a Preliminary Report of a Pilot Study in Celiac Subjects. Antioxidants, 2019, 8, 440.	5.1	4
70	Therapeutic potential for coxibs-nitric oxide releasing hybrids in cystic fibrosis. European Journal of Medicinal Chemistry, 2021, 210, 112983.	5.5	4
71	Development of MmpL3 inhibitors for tuberculosis treatment. Annual Reports in Medicinal Chemistry, 2019, , 71-96.	0.9	3
72	Design, synthesis and antimycotic activity of (N-heteroaryl)arylmethanamines. Journal of Physical Organic Chemistry, 1996, 9, 61-65.	1.9	2

#	Article	IF	Citations
73	Overcoming drugÂresistance in TB: an update. Future Microbiology, 2020, 15, 1607-1609.	2.0	2
74	C-9 Alkenylidine bridged macrolides: WO2008061189. Expert Opinion on Therapeutic Patents, 2009, 19, 901-906.	5.0	1
75	6-Fluorophenylbenzohydrazides inhibit Mycobacterium tuberculosis growth through alteration of tryptophan biosynthesis. European Journal of Medicinal Chemistry, 2021, 226, 113843.	5.5	1